You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新股消息 | 藥明康得、淡馬錫投資的JW(Cayman)向港交所遞表

根據日期為8月14日的披露易文件,JW(Cayman)Therapeutics Co. Ltd.向香港交易所提交了上市申請文件。

JW(Cayman)的股東包括百時美施貴寶、藥明康得和淡馬錫。

高盛和瑞銀是聯席保薦人。

根據初步招股書,上海藥明巨諾獲得對JW(Cayman)的並表聯屬實體財務及運營政策的有效控制權,並有權自其業務獲得所有經濟利益。

根據初步招股書,JW(Cayman)是全球領先的臨床階段細胞治療平臺公司,主打候選產品Relmacabtagene autoleucel(「relma-cel」)是針對復發或難治(「r/r」)B細胞淋巴瘤的抗CD19 CAR-T療法,且國家藥監局已於2020年6月受理審查將relmacel用作DLBCL三線療法的新藥申請。Relma-cel有望成為中國首個獲批的一類生物製品CAR-T療法,並有望成為同類最佳CAR-T療法

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account